# Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

> **NCT03488862** · — · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03488862
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2020-10-28
- **Final completion:** 2020-10-28
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03488862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03488862, "Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03488862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*